Biological therapy for budesonide-refractory, -dependent or -intolerant microscopic colitis: a multicentre cohort study from the GETAID.
Fiche publication
Date publication
juillet 2022
Journal
Journal of Crohn's & colitis
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine, Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Boivineau G, Zallot C, Zerbib F, Plastaras L, Amiot A, Boivineau L, Koch S, Peyrin-Biroulet L, Vuitton L
Lien Pubmed
Résumé
Budesonide remains the backbone therapy for microscopic colitis (MC); however, relapses are frequent, and some patients are intolerant or dependent. Anti-TNF therapy is increasingly used to treat these patients, but available evidence is still limited. The aim of this study was to evaluate the effectiveness and safety of anti-TNF therapy in MC patients failing budesonide.
Mots clés
Anti-TNFα, biologics, budesonide, collagenous colitis, lymphocytic colitis, microscopic colitis, refractory microscopic colitis
Référence
J Crohns Colitis. 2022 07 6;: